Fingolimod; Ocrelizumab/Immunosuppressives; Immune-modulators Interactions

This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.

Medical warning:

Serious. These medicines may interact and cause very harmful effects. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.

How the interaction occurs:

All of these medicines can decrease your body's ability to fight infections.

What might happen:

You may have a higher risk of an infection while taking both medicines.

What you should do about this interaction:

Let your healthcare professionals (e.g. doctor or pharmacist) know right away that you are taking these medicines together or if you have previously taken any immunosuppressives (e.g. medicines for multiple sclerosis or cancer). Let your doctor know if you have any signs of an infection.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.

  • 1.Gilenya (fingolimod) US prescribing information. Novartis Pharmaceuticals Corporation February, 2016.
  • 2.Gilenya (fingolimod) Health Canada prescribing information. Novartis Pharmaceuticals September 23, 2011.
  • 3.Gilenya (fingolimod) UK summary of product characteristics. Novartis Pharmaceuticals UK Ltd June 30, 2015.
  • 4.Ocrevus (ocrelizumab) US prescribing information. Genentech March, 2017.